Form D · Pharmaceuticals
XERIS PHARMACEUTICALS INC
Chicago, IL · CIK 0001346302
Offering snapshot reported May 22, 2017 · SEC filing
- Reported sold
- $30.1M Offering amount: $45M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 17, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 22, 2017 | Initial | $30,050,443 | No comparison | 22 | SEC filing |
| Dec 30, 2016 | Amendment | $45,005,982 | $4,000,002vs Jan 11, 2016 | 48 | SEC filing |
| Jan 11, 2016 | Initial | $41,005,980 | No comparison | 47 | SEC filing |
| Sep 29, 2014 | Initial | $7,274,592 | No comparison | 56 | SEC filing |
| Jul 10, 2013 | Amendment | $2,315,000 | $565,000vs Feb 14, 2013 | 38 | SEC filing |
| Feb 14, 2013 | Amendment | $1,750,000 | $625,000vs Sep 25, 2012 | 28 | SEC filing |
| Sep 25, 2012 | Amendment | $1,125,000 | $900,000vs Jun 8, 2012 | 20 | SEC filing |
| Jun 8, 2012 | Initial | $225,000 | No comparison | 6 | SEC filing |
| Oct 12, 2011 | Amendment | $1,837,848 | $539,100vs Jul 19, 2011 | 19 | SEC filing |
| Jul 19, 2011 | Initial | $1,298,748 | No comparison | 17 | SEC filing |
| Nov 29, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-287198
Series C Preferred Stock
Source: Form D, filed May 22, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Douglas Baum | Director, Executive |
| Doug Baum | Director |
| Shane Brisbin | Director |
| Paul Edick | Director, Executive |
| Robert Faulker | Director |
| Brad Huckabee | Executive |
| Phillip Johnson | Executive |
| John Kinzel | Director, Executive |
| John Kinzell | Director, Executive |
| Cary Mc Nair | Director |
| Steven Prestrelski | Executive |
| Navneet Puri | Director |
| Jonathan Rigby | Director |
| Yash Sabharwal | Executive |
| Mark Saliman | Executive |
| John Shannon | Executive |
| Poul Strange | Executive |
| Timothy Sullivan | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
180 North La Salle Street Ste 1800
Chicago, IL, 60601
Chicago, IL, 60601